ADUCANUMAB E A PROMESSA PARA O FUTURO DO TRATAMENTO DO ALZHEIMER: UMA REVISÃO SISTEMÁTICA

Authors

  • Vitória Souza Saturnino UNIFIP
  • Daysianne Pereira de Lira Uchoa
  • Apolônio Peixoto de Queiroz

DOI:

https://doi.org/10.56083/RCV2N3-031

Keywords:

Alzheimer's disease. Treatment. Aducanumab.

Abstract

ABSTRACT: Alzheimer's disease (AD) is an important public health problem and the most important cause of cognitive impairment in the elderly population. Aducanumab is a disease-modifying monoclonal antibody recently approved by the United States Food and Drug Administration (USFDA) for the treatment of AD. Methods: The present study is a systematic review of the literature, with a qualitative character. As a research tool, the databases to be selected are the Medical Publisher (PUBMED) and Science Direct, with the objective of selecting articles that analyze the effectiveness of the use of Aducanumab in the treatment of Alzheimer's Disease. The analysis criteria involve evaluating, based on the available evidence, the randomized clinical trials, outlining a profile of the obstacles of the researches and the profitable points. Results: Patients with mild to moderate AD who were tested for Aducanumab had some adverse effects that precluded continuation of the study, including amyloid-related imaging abnormalities (ARIA), including edema and microbleeds. Conclusion: Carefully outlining criteria to standardize treatment will be critically important while ensuring access to all elderly AD patients who meet stringent eligibility criteria.

References

BOKHOVEN, Pieter Van; WILDE, Arno de; VERMUNT, Lisa; LEFERINK, Prisca; HEETVELD, Sasja; CUMMINGS, Jeffrey; SCHELTENS, Philip; VIJVERBERG, Everard. The Alzheimer’s disease drug development landscape. Alzheimers Research Therapy, v. 13, p. 186, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34763720/. Acesso em: 13 de maio de 2022. DOI: https://doi.org/10.1186/s13195-021-00927-z

CACABELOS, Ramón; CARRERA, Iván; MARTÍNEZ-IGLESIAS, Olaia; CACABELOS, Natalia; NAIDOO, Vinogran. What is the gold standard model for Alzheimer’s Disease drug discovery and development?. Expert Opinion on Drug Discovery, v. 16, p. 1415-1440, 2021. Disponível em: https://www.tandfonline.com/doi/full/10.1080/17460441.2021.1960502. Acesso em: 15 de maio de 2022. DOI: https://doi.org/10.1080/17460441.2021.1960502

CHHATWAL, Jasmeer; SCHULTZ, Stephanie; MCDADE, Eric; SCHULTZ, Aaron. et al. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. The Lancet Neurology, v. 21, p. 140-152, 2022. Disponível em: https://doi.org/10.1016/S1474-4422(21)00375-6. Acesso em: 01 abr. 2022. DOI: https://doi.org/10.1016/S1474-4422(21)00375-6

CHRISTOPHER, L; CHEN, Qingshu Lu; MOORAKONDA, Rajesh Babu; KANDIAH, Nagaendran; TAN, Boon Yeow; VILLARAZA, Steven Gayoles; CANO, Jemelle; VENKETASUBRAMANIAN, Narayanaswamy. Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial. Journal of the American Medical Directors Association, v. 23, p. 279-286, 2022. Disponível em: https://doi.org/10.1016/j.jamda.2021.10.018. Acesso em: 05 mar. 2022. DOI: https://doi.org/10.1016/j.jamda.2021.10.018

DONATO, Helena; DONATO, Mariana. Etapas na Condução de uma Revisão Sistemática. Acta Médica Portuguesa, v. 32, p. 227-235, 2019. Disponível em: http://dx.doi.org/10.20344/amp.11923. Acesso em: 23 de maio de 2022. DOI: https://doi.org/10.20344/amp.11923

FERRERO, James; WILLIAMS, Leslie; STELLA, Heather; LEITERMANN, Kate; MIKULSKIS, Alvydas; O’GORMAN, John; SEVIGNY, Jeff. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions, v. 2, p. 169-176, 2016. Disponível em: https://doi.org/10.1016/j.trci.2016.06.002. Acesso em: 05 mar. 2022. DOI: https://doi.org/10.1016/j.trci.2016.06.002

GALVÃO, Maria Cristiane Barbosa; RICARTE, Ivan Luiz Marques. Revisão sistemática da literatura: conceituação, produção e publicação. Logeion: Filosofia da Informação, v. 6, p. 57–73, 2019. Disponível em: https://revista.ibict.br/fiinf/article/view/4835. Acesso em: 23 de maio de 2022. DOI: https://doi.org/10.21728/logeion.2019v6n1.p57-73

GLEASON, A; AYTON, S; BUSH, A. I. Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer's clinical trials. European Journal of Neurology, v. 28, p. ___, 2021. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/ene.14484. Acesso em: 23 jan. 2022. DOI: https://doi.org/10.1111/ene.14484

HAEBERLEIN, Samantha Budd; CASTRILLO-VIGUERA, Carmen; GHEUENS, Sarah; CHEN, Tianle; O’GORMAN, John; CHIAO, Ping; WANG, Guanfang; HEHN, Christian von; SKORDOS, LeAnne; HOCK, Christoph; NITSCHM Roger; ROSENSTIEL, Philip von; SANDROCK, Alfred. 24-month analysis of change from baseline in clinical dementia rating scale cognitive and functional domains in prime: a randomized phase 1b study of the anti–amyloid beta monoclonal antibody aducanumab. Alzheimer's & Dementia, v. 14, p. 242, 2018. Disponível em: https://doi.org/10.1016/j.jalz.2018.06.2383. Acesso em: 09 jan. 2022. DOI: https://doi.org/10.1016/j.jalz.2018.06.2383

HERRING, William; GOULD, Ian Gopan; FILLIT, Howard; LINDGREN, Peter; FORRESTAL, Fiona; THOMPSON, Robin; PEMBERTON-ROSS, Peter. Predicted lifetime health outcomes for aducanumab in patients with early Alzheimer’s Disease. Neurology and Therapy, v. 10, p. 1-21, 2021. Disponível em: https://link.springer.com/article/10.1007/s40120-021-00273-0. Acesso em: 22 de maio de 2022. DOI: https://doi.org/10.1007/s40120-021-00273-0

JAFFE, Susan. US FDA defends approval of Alzheimer’s Disease Drug. The Lancet, v. 398, p. 11-12, 2021. Disponível em: https://www.thelancet.com/journals/lancet/article/PIIS01406736(21)01455-0/fulltext. Acesso em: 22 de maio de 2022. DOI: https://doi.org/10.1016/S0140-6736(21)01455-0

MUKHOPADHYAY, Sanchari; BANERJEE, Debanjan. A primer on evolution of aducanumab: The first antibody approved for treatment of Alzheimer’s Disease. Journal of Alzheimer’s Disease, v. 83, p. 1537-1552, 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34366359/. Acesso em: 21 jan. 2022. DOI: https://doi.org/10.3233/JAD-215065

MULLARD, Asher. Alzheimer’s drug approval could afect other diseases. Nature, v. 595, p. 162-163, 2021. Disponível em: https://www.nature.com/articles/d41586-021-01763-9. Acesso em: 23 de maio de 2022. DOI: https://doi.org/10.1038/d41586-021-01763-9

MURALIDHARAN, Kandadi; TONG, Xiao; KOWALSKI, Kenneth; RAJAGOVIDAN, Raj; LIN, lin; HABERLAIN, Samantha; NESTOROV, Ivan. Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease. CPT: Pharmacometrics & Systems Pharmacology, v. 11, p. 7-19, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34697913/. Acesso em: 22 fev. 2022. DOI: https://doi.org/10.1002/psp4.12728

ROSENSTIEL, Philip von; CASTRILLO-VIGUERA, Carmen; GHEUEMS, Sarah; CHEN, Tiantle; O’GORMAN, John; CHIAO, Ping; WANG, Guanfang; HEHN, Christian Von; SKORDOS, Leanne; HOCK, Christoph; NITSCH, Roger; HAEBERLEIN, Samantha Budd; SANDROCK, Alfred. Month analysis of apoe ε4 carriers in prime: a randomized phase 1b study of the anti–amyloid beta monoclonal antibody aducanumab. Alzheimer's & Dementia, v. 14, p. 283, 2018. Disponível em: https://doi.org/10.1016/j.jalz.2018.06.042. Acesso em: 02 abr. 2022. DOI: https://doi.org/10.1016/j.jalz.2018.06.042

SALLOWAY, Stephen; CHALKIAS, Spyros; BARKHOF, Frederik. et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA neurology, v. 79, p. 13-21, 2022. Disponível em: https://jamanetwork.com/journals/jamaneurology/fullarticle/2786606. Acesso em: 13 de maio de 2022. DOI: https://doi.org/10.1001/jamaneurol.2021.4161

SPRINGER, Seth; WIESMAN, Alex; MAY, Pamela. et al. Visual entrainment responses are altered in patients with mild cognitive impairment and Alzheimer’s disease. Alzheimer's & Dementia, v. 17, p. 1, 2021. Disponível em: https://doi.org/10.1002/alz.054546. Acesso em: 14 jan. 2022. DOI: https://doi.org/10.1002/alz.054546

VIGLIETTA, Vissia; O’GORMAN, John; WILLIAMS, Leslie; CHEN, Tiantle; CHIAO, Ping; BOOT, Brendon; HOCK, Christoph; NITSCH, Roger; SANDROCK, Alfred. Clinical dementia rating-sum of boxes responder analysis in prime: a randomized phase 1b study of the anti-amyloid beta monoclonal antibody aducanumab (biib037). Alzheimer's & Dementia, v. 12, p. 416, 2016. Disponível em: https://doi.org/10.1016/j.jalz.2016.06.787. Acesso em: 02 de maio de 2022. DOI: https://doi.org/10.1016/j.jalz.2016.06.787

Published

2022-05-31

How to Cite

Souza Saturnino, V., Pereira de Lira Uchoa, D., & Peixoto de Queiroz, A. (2022). ADUCANUMAB E A PROMESSA PARA O FUTURO DO TRATAMENTO DO ALZHEIMER: UMA REVISÃO SISTEMÁTICA. Revista Contemporânea, 2(3), 658–676. https://doi.org/10.56083/RCV2N3-031

Issue

Section

Articles